Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma Slams Amarin In Vascepa Antitrust Suit For ‘Locking Up API Supply’

Fellow Icosapent ANDA Sponsor Dr Reddy’s Also Previously Filed Antitrust Suit

Executive Summary

Amarin is facing up to another antitrust lawsuit over its alleged control of API supply for its Vascepa brand.

You may also be interested in...



No “Constraining Situation” On gVascepa API Says Strides MD, Q3 Revenues Jump

Strides intends to keep US momentum going with Amneal-partnered generic Vascepa, where Hikma and Dr. Reddy’s have filed antitrust suits against Amarin over API supply. Meanwhile, the founder re-iterated ambitious goals set for Stelis and its CDMO business

Amneal Taps Strides To Add More Competition To US Vascepa Market

Amneal has in-licensed Strides’ generic version of Vascepa to compete with the several ANDA products already on the market.

Amarin Is Prepared To Be ‘Aggressive’ With Vascepa Authorized Generic

Amarin’s management has suggested that it would be prepared to compete “very aggressively” with a US authorized generic version of its Vascepa if and when it decides to launch. The comments came as the originator named a new CEO and restructured in the wake of increasing generic competition.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel